Jump to Navigation


The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to address HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians.


Recent News
Feb 22, 2017

Aethlon Medical, Inc. (Nasdaq: AEMD), today reported the results of a study that validated the ability of the Aethlon Hemopurifier® to capture latent viral pathogens that are associated with...

Feb 10, 2017

Aethlon Medical, Inc. (Nasdaq: AEMD), a developer of immunotherapeutic technologies to combat infectious disease and cancer, today announced results for its fiscal third quarter year ended...

View all News Releases

Friday, February 10, 2017
4:30pm EST

What: Aethlon's Third Quarter 2017 Investor Conference Call and Audio Webcast Date: Friday, February 10, 2017 Time: 4:30 p.m. Eastern Time Live call: 844-836-8741 International: 412-317-5442 Audio...

Thursday, November 10, 2016
4:30pm EST

View All Events

print email

Back to Top

Site 'Subpage' Navigation:

Investor Relations

Investor Contact

Aethlon Medical, Inc.

Back to Top